Eli Lilly vs Novo Nordisk: Which Is the Better Buy in 2026?

Novo Nordisk is a purer GLP-1 play — Ozempic and Wegovy represent the overwhelming majority of its revenue and market identity. Lilly has GLP-1 (Mounjaro/Zepbound) alongside oncology, immunology, and Alzheimer's (donanemab) as a pipeline that diversifies GLP-1 dependence meaningfully. Novo's story is more concentrated; Lilly's is broader. If GLP-1 pricing ever comes under pressure from generics or policy, Lilly has more cushion. For concentrated GLP-1 exposure, Novo. For diversified biopharma with GLP-1 as the primary catalyst, Lilly.

Both Eli Lilly and Novo Nordisk are generating extraordinary revenue from GLP-1 obesity and diabetes drugs, but the manufacturing race will determine which company owns the larger share of what may be the biggest pharmaceutical market in history. Novo has first-mover advantage and strong global formulary positions. But Lilly's tirzepatide (Mounjaro/Zepbound) has shown superior weight loss in head-to-head data, and Lilly's US manufacturing build is aggressive. The bull case for Lilly is straightforward: if the drug with better efficacy wins in a market this large, Lilly takes more of the upside. The risk is whether manufacturing can match demand before Novo locks in long-term formulary access.